We succeeded in finding a single dataset meeting this criteria: a study of patients with non-small cell lung cancer who initially responded to ICB (anti-PD-1/PD-L1±anti-CTLA-4 Ab) but later developed resistance28. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.